AAV Vector Epitope Removal for T-Cell Immune Evasion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Gene therapy approaches using adeno-associated virus (AAV) vectors face challenges due to immune responses, particularly T-cell mediated destruction of transgene-expressing cells, which limits the longevity and effectiveness of gene expression in humans.
Innovation Solution
Development of soluble T-cell receptors (sTCRs) specific to AAV epitopes presented on human MHC Class I molecules, allowing for detection and inhibition of T-cell responses, and modification of AAV vectors to eliminate immunogenic epitopes, thereby preventing T-cell mediated destruction of transduced cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AAV vectors are used for gene therapy, then gene transfer and expression are achieved, but T-cell mediated immune response destroys transgene-expressing cells
Solution Approach 1:
The patent extracts and identifies specific immunogenic epitopes from the AAV capsid proteins (VP1, VP2, VP3) that are recognized by T cells. By isolating these specific peptide sequences (e.g., VP1 residues 1-10, VP2 residues 1-10, VP3 residues 1-10), the invention enables targeted modification of the vector to remove or alter these harmful epitopes, thereby preventing T-cell recognition and destruction while preserving gene expression capability.
Solution Approach 2:
The patent applies parameter changes by modifying the amino acid sequence of the AAV capsid proteins at specific positions where immunogenic epitopes are located. By altering the peptide sequences (e.g., changing residues in the capsid proteins) while maintaining overall vector structure and function, the invention changes the immunological parameters to reduce T-cell recognition. This allows the vector to evade immune detection while still delivering the therapeutic gene.
2Reliability
If immune response is suppressed to prevent T-cell destruction, then transgene expression is maintained, but immune-related complications arise
Solution Approach 1:
The patent applies preliminary action by pre-identifying and pre-modifying the AAV vector to eliminate immunogenic epitopes before administration to the patient. By preparing the vector in advance with altered capsid sequences that avoid T-cell recognition, the invention prevents immune-related complications from arising in the first place, rather than suppressing immune responses after they occur. This proactive approach maintains transgene expression while avoiding immune complications.
3Ease of manufacture
If AAV vectors with immunogenic capsids are used, then vector production is simplified, but T-cell recognition leads to vector clearance
Solution Approach 1:
The patent extracts and removes specific immunogenic epitopes from the AAV capsid protein sequences used in vector production. By isolating the harmful peptide sequences (e.g., specific residues in VP1, VP2, VP3) and eliminating or altering them during vector construction, the invention maintains a simplified production process while ensuring the resulting vector does not trigger T-cell recognition and clearance.
Solution Approach 2:
The patent applies parameter changes by modifying the capsid protein sequences during vector manufacturing to alter immunogenicity parameters. By changing specific amino acid residues in the capsid proteins (e.g., mutating epitope sequences) while maintaining overall vector structure and manufacturability, the invention creates vectors that are easier to produce but resistant to T-cell mediated clearance, thereby improving vector persistence in the host.
Data Source
AI summary
Compositions and methods are provided for inhibiting T cell mediated destruction of virally transduced, trangene containing cells.